Grant: Operating Grant
University of British Columbia
$403,528.00
High throughput analysis of RNA-seq reads to characterize alternative polyadenylation in myeloid malignancy
FY 2013-14
Summary
When a gene is activated, it is copied ("transcribed") from DNA into a string of molecules called a messenger RNA (mRNA). The middle section of each mRNA encodes the information that is translated into the corresponding protein sequence; the two ends, called untranslated regions (UTRs), play a number of other important roles. This proposal concerns the tail end of the mRNA, known as the 3' UTR, which helps to regulate the stability and location of the mRNA and the amount of the corresponding protein that is produced.
The point at which the transcription of a given mRNA ends is determined by the presence of a sequence called a polyadenylation site. Some genes have more than one such site, meaning that there can be two or more different forms of the corresponding mRNA, with different 3' UTRs and therefore different levels of activity. Changes in the ratio of the different
forms are thought to contribute to the development of a range of disorders, including some cancers.
The methods currently used to study polyadenylation require an extra set of experiments to be run, which is expensive and slow. However, Drs. Birol and Karsan and their teams have obtained evidence that polyadenylation can be studied alongside other important types of transcriptional regulation, using data from experiments that are already performed as part of standard analysis. They propose to develop a method to integrate polyadenylation analysis with these standard analyses, and to test the new method by characterizing how the use of different polyadenylation sites changes in a type of leukemia.
Department
Program
Operating Grant
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
303496
Name
Birol Inanc
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Genetics
Theme2
Biomedical
Prcname2
Genomics: Systems and computational biology
Projecttitle
High throughput analysis of RNA-seq reads to characterize alternative polyadenylation in myeloid malignancy
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$403,528
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Acute Myeloid Leukemia; Polyadenylation; Rna-Seq; Transcriptional Regulation; Transcriptome Assembly
Abstract
When a gene is activated, it is copied ("transcribed") from DNA into a string of molecules called a messenger RNA (mRNA). The middle section of each mRNA encodes the information that is translated into the corresponding protein sequence; the two ends, called untranslated regions (UTRs), play a number of other important roles. This proposal concerns the tail end of the mRNA, known as the 3' UTR, which helps to regulate the stability and location of the mRNA and the amount of the corresponding protein that is produced.
The point at which the transcription of a given mRNA ends is determined by the presence of a sequence called a polyadenylation site. Some genes have more than one such site, meaning that there can be two or more different forms of the corresponding mRNA, with different 3' UTRs and therefore different levels of activity. Changes in the ratio of the different
forms are thought to contribute to the development of a range of disorders, including some cancers.
The methods currently used to study polyadenylation require an extra set of experiments to be run, which is expensive and slow. However, Drs. Birol and Karsan and their teams have obtained evidence that polyadenylation can be studied alongside other important types of transcriptional regulation, using data from experiments that are already performed as part of standard analysis. They propose to develop a method to integrate polyadenylation analysis with these standard analyses, and to test the new method by characterizing how the use of different polyadenylation sites changes in a type of leukemia.
Competitiondate
201403
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Birol, Inanc
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $403,528~ $0~